Global Long-Acting Injectable Drugs Market Research Report 2021 with Forecasts to 2028 – ResearchAndMarkets.com | Business

DUBLIN–(BUSINESS WIRE)–Jan 26, 2022–

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns.

These, which are not new, are becoming magnified as the number of powerful new drugs reaching the concerns increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Formulation Using technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles.

These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

  • What are the marketed long-acting injectable drug products, what long-acting formulation technologies are used, and who markets them?
  • What are the major factors driving long-acting injectable drug demand?
  • What long-acting injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the long-acting market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for long-acting injectable drug products?
  • In what therapeutic market segments do long-acting injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for long-acting injectables?
  • Long-Acting Injectable Drugs
  • Executive Summary
  • Injectable Drug Market Dynamics
  • The trend toward self-administration

Injectable Drug Formula

  • Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers
  • Patient Compliance
  • Ease of Use
  • Healthcare Regulations
  • Managed Care Initiatives
  • Competitive Landscape
  • Risk Factors
  • Biodegradable Polymers
  • PEG
  • PLA/PLGA
  • Polyether ester
  • Long-Acting Injectable Formulation Technologies
  • BEPO (MedinCell)
  • ChroniJect (Oakwood Laboratories/PharmaSophia)
  • CriticalMix (Critical Pharmaceuticals)
  • Depofoam (Pacira)
  • FluidCrystal (Camarus)
  • LinkeRx (Alkermes)
  • Medisorb (Alkermes)
  • Medusa (Recipharm/Avadel)
  • Nanocrystals (Alkermes)
  • Optisomes (Talon/Spectrum)
  • PolyActive (Octoplus)
  • Q-Sphera (Midatech Pharma)
  • SABER/SAIB (DURECT)
  • SynBiosys (Innocore)
  • TransCon (Ascendis)
  • Methods
  • Supercritical Fluid
  • SCF for Nanoparticle Formulations
  • Formulplex (Supercritical Solutions)
  • Ferro SCF extraction of emulsions (SFEE)

Long-Acting Injectables – Development Factors

  • Formulation Factors
  • Stability
  • Administration Factors
  • Long-Acting Product Analysis
  • Aripiprazole
  • Aripiprazole lauroxil
  • Bupivacaine
  • Buprenorphine
  • Cytarabine
  • Cytarabine & Daunorubicin
  • Doxorubicin
  • Estradiol
  • Exenatide
  • Fluphenazine decanoate
  • Goserelin acetate
  • Granisetron
  • Interferon (1)
  • Interferon (2)
  • Interferon (3)
  • Interferon (4)
  • Irinotecan
  • Lanreotide acetate
  • Leuprolide
  • Leuprolide Depot
  • Medroxyprogesterone
  • naltrexone
  • Octreotide acetate
  • Olanzapine Pamoate
  • Paliperidone palmitate
  • Pasireotide
  • Pegvaliase-pqpz
  • Risperidone
  • Testosterone
  • Triptorelin (1)
  • Triptorelin (2)
  • Triamcinolone acetonide
  • Vincristine sulfate
  • Glycemic Control
  • AB101 (Rezolute)
  • Hormone Deficiency
  • human growth hormone/
  • Ascendis Pharma
  • Addiction
  • CAM2038 (Camurus)
  • Pain Management
  • Posidur/Durect
  • Cardiology
  • Treprostinil/Ascendis Pharma
  • Neurology
  • Relday/Risperidone (DURECT/Zogenix)
  • Oncology
  • CAM2032 (Camurus)

Therapeutic Sector Analysis

  • Addiction
  • Glycemic Control
  • Infectious Disease
  • Hepatitis
  • Neurology
  • Schizophrenia
  • Bipolar Disorder
  • Oncology
  • Pain Management
  • Reproductive Health
  • Fertility
  • Endometriosis
  • Alkermes
  • Amylin
  • AntriaBio
  • Ascendis Pharma
  • AstraZeneca
  • Aurobondo
  • Avadel
  • Biomarin
  • Camurus
  • Critical Pharmaceuticals
  • DURECT
  • Eli Lilly
  • Enzon
  • Ipsen
  • Jansen
  • NanOlogy
  • Novartis
  • Oakwood Laboratories/PharmaSophia
  • OctoPlus
  • Pacira
  • PhaseBio Pharmaceuticals
  • Recipharm AB
  • Roche
  • Sanofi
  • Taiwan Liposome Company (TLC)
  • Xbrane Bipharma

Laura Wood, Senior Press Manager

For EST Office Hours Call 1-917-300-0470

For US/CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.

PUB: 01/26/2022 09:35 AM/DISC: 01/26/2022 09:36 AM

Copyright Business Wire 2022.

.

Leave a Comment